These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21817186)

  • 21. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
    Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
    Notari S; Sergi M; Montesano C; Ivanovic J; Narciso P; Pucillo LP; Ascenzi P
    IUBMB Life; 2012 May; 64(5):443-9. PubMed ID: 22473795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.
    Huesgen E; Burgos R; Goldstein DA; Max B; Jarrett OD
    Antivir Ther; 2012; 17(7):1385-8. PubMed ID: 22728657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
    Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
    Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
    Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
    Valerio L; Fontas E; Pradier C; Lavrut T; Garraffo R; Dunais B; Cua E; Dellamonica P
    J Infect; 2005 Apr; 50(3):229-35. PubMed ID: 15780417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
    Eron JJ; Feinberg J; Kessler HA; Horowitz HW; Witt MD; Carpio FF; Wheeler DA; Ruane P; Mildvan D; Yangco BG; Bertz R; Bernstein B; King MS; Sun E
    J Infect Dis; 2004 Jan; 189(2):265-72. PubMed ID: 14722892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.